These data provide for the first time a foundation to further explore the mechanism by which ADAM19 exerts its tumor suppressor effects and raises the possibility that expression of ADAM19 levels in prostate cancer tumors could become a useful biomarker in the disease. Here, ADAM19 is linked to prostate cancer.